Title : Rapid Response to Lorlatinib in a Patient With TFG-ROS1 Fusion Positive Inflammatory Myofibroblastic Tumor of the Chest Wall Metastatic to the Brain and Refractory to First and Second Generation ROS1 Inhibitors.

Pub. Date : 2021 Jul 1

PMID : 34157012






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Crizotinib has been effective in ALK and ROS1-positive IMTs but resistance eventually develops. Crizotinib ROS proto-oncogene 1, receptor tyrosine kinase Homo sapiens